Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides

(2011) Kanchan Kantekure et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

(2011) Y. H. Kim et al.   BLOOD

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

(2011) R. B. Sorensen et al.   CANCER RESEARCH

Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome

(2011) T Krejsgaard et al.   LEUKEMIA

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

(2010) R. B. Sorensen et al.   BLOOD

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase

(2009) Rikke Bæk Sørensen et al.   PLoS One